Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Shorla Oncology

Our CEO part of the “Cancer Across Borders – Ireland’s Reach” Panel Discussion

December 12th 2022

Read More

Banner

Join Shorla Oncology at CPhI Frankfurt 2022

October 19th 2022October 19th 2022

Read More

Banner

Shorla Oncology at Bio Europe 2022

October 13th 2022October 13th 2022

Read More

Photo

Our CTO spoke on the founders panel at Scale Ireland’s Annual Event

October 5th 2022September 12th 2022

Read More

Banner

Our CEO spoke at the LSX World Congress USA in Boston

July 21st 2022June 21st 2022

Read More

Banner

Shorla Oncology at ASCO Annual Meeting, Chicago 2022

May 30th 2022

Read More

Photo

Our CCO, Nicholas Holsman speaks at the MassBio Conference

May 25th 2022May 5th 2022

Read More

Dennis

Shorla Oncology Appoints Dennis Purcell as Chairman

April 1st 2022March 29th 2022

Read More

Shorla Oncology

Company Name Change: Shorla Pharma is now Shorla Oncology!

March 10th 2022

Read More

Older posts
Newer posts
Page1 … Page6 Page7 Page8 … Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.